We are live on ! Find out more
MAM

MPM Asset Management Portfolio holdings

AUM $44.5M Turnover 20%
1-Year Est. Return 47.28%
This Fund
S&P 500
This Quarter Est. Return
+1.79%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$204M
AUM Growth
-$36.1M
Cap. Flow
-$37.5M
Cap. Flow %
-18.39%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
–
Closed
2
Avg Time Held
2.3 years
Top 10 Avg Time Held
2.3 years
Top 20 Avg Time Held
2.3 years

Top Buys

Rank Stock Value
1
ADAP
Adaptimmune Therapeutics
ADAP
+$7.5M

Top Sells

Rank Stock Value
1
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$38.9M
2
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
+$6.08M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TRDA icon
1
Entrada Therapeutics
TRDA
$177M
$67M 32.86%
4,425,784
– –
2021 Q4
6 quarters
DYN icon
2
Dyne Therapeutics
DYN
$2.81B
$55.7M 27.32%
4,951,303
– –
2020 Q3
11 quarters
ITOS icon
3
DELISTED
iTeos Therapeutics
ITOS
$36.3M 17.78%
2,738,785
– –
2020 Q3
11 quarters
RPTX icon
4
DELISTED
Repare Therapeutics
RPTX
$23.7M 11.64%
2,242,636
– –
2020 Q2
12 quarters
HOWL icon
5
Werewolf Therapeutics
HOWL
$47.6M
$13.1M 6.41%
4,284,172
– –
2021 Q2
8 quarters
ADAP
6
DELISTED
Adaptimmune Therapeutics
ADAP
$5.82M 2.85%
+6,287,101
New +$7.5M
2023 Q2
0 quarters
HARP
7
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.22M 1.09%
313,139
– –
2019 Q1
17 quarters
ONCR
8
DELISTED
Oncorus, Inc.
ONCR
$115K 0.06%
2,849,464
– –
2020 Q4
10 quarters
TCRR
9
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-4,050,865
Closed -$6.08M –
AMYT
10
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
– –
-2,668,843
Closed -$38.9M –

Similar funds

WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

MPM Asset Management's Q2 2023 Portfolio in Review

As of Q2 2023, MPM Asset Management held 10 positions worth $204M, down 15% from $240M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

MPM Asset Management withdrew a net $37.5M in Q2 2023, closing 2 positions. Its most notable exit was Amryt Pharma plc American Depositary Shares, an estimated $38.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, MPM Asset Management opened a new position in Adaptimmune Therapeutics worth $5.82M.

  • MPM Asset Management's largest Q2 2023 buy was Adaptimmune Therapeutics: 6,287,101 shares worth $5.82M.
  • MPM Asset Management fully exited Amryt Pharma plc American Depositary Shares in Q2 2023, selling an estimated $38.9M.
  • MPM Asset Management's ten largest holdings make up 100% of its $204M portfolio in Q2 2023.
  • MPM Asset Management opened 1 new position and closed 2 in Q2 2023.
  • MPM Asset Management's portfolio value fell 15% quarter-over-quarter to $204M.

Based on MPM Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.